AS-56: Impact of Olmesartan on Progression of Coronary Atherosclerosis: A Serial Volumetric Intravascular Ultrasound Analysis from the OLIVUS Trial

Hirohata, Atsushi; Yamaji, Hirosuke; Murakami, Masaaki; Hirose, Eiki; Ohkawa, Kazushi; Ishizawa, Makoto; Sato, Shinji; Yamamoto, Keizô; Miyoshi, Toru; Kusachi, Shouzou; Hatanaka, Kunihiko; Yamawaki, Hitoshi; Komatsubara, Issei

doi:10.1016/j.amjcard.2009.01.102

Cited by 37 publications

(57 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, a sustained antihypertensive effect of olmesartan was found in the patients with dyslipidemia, suggesting that the antihypertensive effects of the RAS inhibitor olmesartan 19) may have helped to prevent CVD in this group of patients. Furthermore, it is possible that effects of the RAS inhibitor other than its antihypertensive effects, such as anti-inflammatory effects 20) and/or prevention of the progression of coronary atherosclerosis 21) , may have contributed to the preventive effects against CHD observed in the hypertensive patients with dyslipidemia; however, further studies are needed to verify this speculation.…”

Section: Discussionmentioning

confidence: 87%

Lipid and Blood Pressure Control for the Prevention of Cardiovascular Disease in Hypertensive Patients: A Subanalysis of the OMEGA Study

Teramoto

Kawamori

Miyazaki

et al. 2015

J Atheroscler Thromb

View full text Add to dashboard Cite

Aim:The aim of this analysis was to investigate the relationships between dyslipidemia, achieved blood pressure (BP) values and the lipid levels, as well as the control of four cardiovascular risk factors (BP, low-density lipoprotein: LDL cholesterol, hemoglobin A1c: HbA1c and smoking) and the incidence of cardiovascular disease (CVD), in Japanese patients receiving antihypertensive therapy. Methods: A total of 13,052 patients with no history of CVD were included in this subanalysis of the prospective observational OMEGA study in Japanese hypertensive patients treated with olmesartan. Multivariable Cox regression models were used to evaluate the relationship with the risk of CVD. Results: The incidence of CVD during the 36-month study period was 5.59/1,000 patient-years among the patients with dyslipidemia (n 6,297) and 5.57/1,000 patient-years among the patients without dyslipidemia (n 6,755), with no significant differences between the two groups. Higher achieved BP values tended to be associated with an increased CVD risk in both the patients with and without dyslipidemia. In addition, the risk of CVD tended to be higher in the patients with an achieved LDL cholesterol level of ≥ 120 mg/dL than in those with an LDL level of 120 mg/dL (trend p 0.0005) and in the patients with an achieved high-density lipoprotein cholesterol level of 60 mg/dL than in those with an HDL level of ≥ 60 mg/dL (trend p 0.0017). Furthermore, the risk of CVD was higher among the patients with fewer controlled risk factors than among those with control of all four risk factors (trend p 0.0001). Conclusions: In order to prevent CVD in olmesartan-treated hypertensive patients with no history of CVD, it is important to control both the lipid and BP levels and aim for comprehensive risk factor control.J Atheroscler Thromb, 2015; 22:62-75.

show abstract

Section: Discussionmentioning

confidence: 87%

Lipid and Blood Pressure Control for the Prevention of Cardiovascular Disease in Hypertensive Patients: A Subanalysis of the OMEGA Study

Teramoto

Kawamori

Miyazaki

et al. 2015

J Atheroscler Thromb

View full text Add to dashboard Cite

show abstract

“…15 Moreover, the treatment of these patients with olmesartan increased the protein expression of heme oxygenase-1, 15 a potent antioxidant and anti-inflammatory protein, 16,17 and the number of cEPCs and reduced cEPCs apoptosis in addition to increase the level of calcitonin generelated peptide, 18 a vasorelaxant that prevents cEPCs senescence, reverses Ang II-induced senescence of EPCs and reduces blood pressure in spontaneously hypertensive rats. 19 Furthermore, although indirectly, the vasoprotective, antiinflammatory and anti-atherosclerotic effects of olmesartan shown in humans in the European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA), Vascular Improvement with Olmesartan medoxomil Study (VIOS), Multicenter Olmesartan Atherosclerosis Regression Evaluation (MORE) and Impact of OLmesartan on progression of coronary atherosclerosis: Evaluation by IntraVascular UltraSound (OLIVUS) clinical trials [23][24][25][26] can be linked with an inhibitory effect on oxidative stress and oxidative stress signaling as a mechanism involved in the effects of olmesartan observed in these studies. Given these effects of olmesartan on oxidative stress and on the improvement of endothelial dysfunction including inflammatory processes mediated by Ang II and given that RhoA/Rho kinase activation, as mentioned above, is mainly involved in the Ang II signaling following Ang II AT1R activation including oxidative stress, [1][2][3]9 it comes as no surprise that olmesartan may be able to downregulate the RhoA/Rho kinase pathway via AT1R blockade and reduction of oxidative stress effects.…”

Section: Discussionmentioning

confidence: 99%

The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling

Ravarotto

Pagnin

Maiolino

et al. 2015

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

Hypothesis/Introduction: The pathophysiological role of oxidative stress (OxSt) in hypertension and target organ damage is recognized. Angiotensin II (Ang II) induces OxSt via NAD(P)H oxidase activation and production of proinflammatory cytokines/growth factors leading to cardiovascular-renal remodeling. Ang II stimulates the RhoA/Rho kinase (ROCK) pathway, which is deeply involved in the development of cardiovascular-renal remodeling via OxSt induction. Olmesartan, an Ang II type 1 receptor blocker, possesses antioxidant and activating nitric oxide system-related effects, which we have shown in terms of p22phox reduction, heme oxygenase-1 and calcitonin gene-related peptide increase. This study evaluates in 15 untreated hypertensive patients the effect of olmesartan treatment on p63RhoGEF, key in Ang II-induced ROCK activation, and MYPT-1 phosphorylation, a marker of ROCK activity. Materials and methods: The p63RhoGEF protein level and MYPT-1 phosphorylation (Western blot) were evaluated at baseline, and after three and six months of olmesartan treatment. Results: Olmesartan normalized systolic and diastolic BP (p < 0.001), reduced p63RhoGEF level: 1.3±0.25 d.u. (baseline) vs 1.0±0.29 (three months), p < 0.0001 vs 1.0±0.22, (six months), p < 0.0001 and MYPT-1 phosphorylation: 1.2 ±0.14 (baseline) vs 0.9±0.19 (three months), p = 0.008, vs 0.8±0.16 (six months), p = 0.001. Conclusions: These data added to our previous results further provide a mechanistic rationale for olmesartan’s antioxidant/anti-inflammatory potential translation, in the long term, toward anti-atherosclerotic/anti-remodeling effects reported by clinical trials.

show abstract

“…Кумулятивная, свободная от нежелательных событий, выживаемость в группе олмесартана оказа-лась значительно выше, чем в группе плацебо. Тера-пия олмесартаном была признана хорошим способом профилактики "больших" (major) кардио -и цереб-роваскулярных нежелательных эффектов [15,16].…”

Section: российскийunclassified

Difficult choice: angiotensin receptor antagonists

Таратухин¹

2013

Russ J Cardiol

View full text Add to dashboard Cite

The paper is focussed on the therapeutic choice of angiotensin receptor antagonists (ARA). The author presents the data on the comparison between different sartans and their benefits which are not explained by the blood pressure reduction. The findings from large multi-centre studies (EUTOPIA, DOHSAM, and OLIVUS-Ex) are also discussed. The evidence presented justifies specific ARA choices, despite the fact that at a first glance, this medication class appears homogeneous. Russ J Cardiol 2013; 2 (100): 94-97

show abstract

AS-56: Impact of Olmesartan on Progression of Coronary Atherosclerosis: A Serial Volumetric Intravascular Ultrasound Analysis from the OLIVUS Trial

Cited by 37 publications

References 0 publications

Lipid and Blood Pressure Control for the Prevention of Cardiovascular Disease in Hypertensive Patients: A Subanalysis of the OMEGA Study

Lipid and Blood Pressure Control for the Prevention of Cardiovascular Disease in Hypertensive Patients: A Subanalysis of the OMEGA Study

The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling

Difficult choice: angiotensin receptor antagonists

Contact Info

Product

Resources

About